Publications

* REPRINT AVAILABILITY IS FOR PERSONAL USE ONLY - ANYONE DOWNLOADING REPRINTS AGREES TO OBEY ALL COPYRIGHT LAWS PERTAINING TO THE ARTICLE 

​​​

Goltseker, K., Handrus, H., Barak, S. (2020). Disruption of relapse to alcohol seeking by aversive counterconditioning following memory retrieval. Addiction Biology, e12935. Advance online publication. https://doi.org/10.1111/adb.12935PDF

 

Edemann-Callesen, H., Barak, S., Hadar, R., & Winter, C. (2020). Choosing the Optimal Brain Target for Neuromodulation Therapies as Alcohol Addiction Progresses—Insights From Pre-Clinical Studies. Current Addiction Reports, 1-8. PDF

Liran, M., Rahamim, N., Ron, D., & Barak, S. (2020). Growth factors and alcohol use disorder. Cold Spring Harbor perspectives in medicine, a039271. PDF

Maier, H.B., Neyazi, M., Neyazi, A., Hillemacher, T., Pathak, H., Rhein, M., Bleich, S., Goltseker, K., Sadot-Sogrin, Y., Even-Chen, O., Frieling, H., Barak S.  (2020). Alcohol consumption alters Gdnf promoter methylation and expression in rats. Journal of Psychiatric Research, 121: 1-9. PDF

Even-Chen O., Barak S. (2019). Inhibition of FGF receptor-1 suppresses alcohol consumption: role of PI3 kinase signaling in dorsomedial striatum. The Journal Of Neuroscience  39 (40), 7947-7957. PDF

Gera R., Barak S., Schonberg T. (2019). Counterconditioning following memory retrieval diminishes the reinstatement of appetitive memories in humans. Scientific Reports 9(1):9213PDF

Even-Chen O., Barak S. (2019). The role of fibroblast growth factor 2 in drug addiction. European Journal of Neuroscience,50:2552–2561PDF

Goltseker, K., Hopf, F. W., Barak, S. (2019). Advances in behavioral animal models of alcohol use disorder. Alcohol, 74:73-82PDF

Ziv Y., Rahamim N., Lezmy N., Even Chen O., Shaham, O. Malishkevich A., Giladi E.. Elkon R., Gozes I., Barak S. (2019). Activity-dependent neuroprotective protein is a novel negative regulator of alcohol consumption in female mice. Neuropsychopharmacology, 44(2):415-424. PDF

Barak, S., Ahmadiantehrani, S., Logrip, M. L., Ron, D. (2019). GDNF and alcohol use disorder. Addiction Biology, 24(3):335-343. PDF

Goltseker, K., Barak, S. (2018). Flood-conditioned place aversion as a novel non-pharmacological aversive learning procedure in mice. Scientific Reports, 8(1), 7280PDF

Burstein O., Gale E., Handelsman A., Barak S., Franko M., Motsan S., Shamir A., Toledano R., Simhon O., Hirshler Y., Doron R. (2017). Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS One 12(11): e0188043. PDF

Even-Chen O., Sadot-Sogrin Y., Shaham O., Barak S. (2017). Fibroblast growth factor 2 in the dorsomedial striatum is a novel positive regulator of alcohol consumption. The Journal Of Neuroscience 37(36):8742-8754. PDF

Zipori D., Sadot-Sogrin Y., Goltseker K., Even-Chen O., Rahamim N., Shaham O., Barak S. (2017). Re-exposure to nicotine-associated context from adolescence enhances alcohol intake in adulthood. Scientific Reports 7(1):2479. PDF

Goltseker K., Bolotin L., Barak S. (2017). Counterconditioning during reconsolidation prevents relapse of cocaine memories. Neuropsychopharmacology 42(3):716-726PDF

Ron D., Barak S. (2016). Molecular mechanisms underlying alcohol-drinking behaviours. Nature Reviews Neuroscience, 17: 576-591. PDF

Logrip M.L., Barak S., Warnault V. Ron D. (2015). Corticostriatal BDNF and alcohol addiction. Brain Research, 1628:60-67PDF

Barak S., Wang J., Ahmadiantehrani S., Ben Hamida S, Kells A.P., Forsayeth J., Bankiewicz K.S., Ron D. (2015). GDNF is an endogenous protector in the mesolimbic system against excessive alcohol consumption and relapse. Addiction Biology, 20: 629-642 . PDF

Weiner I., Barak S. (2015). Latent Inhibition. In I.P. Stolerman and L.H Price (Eds) Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg. PDF

Carnicella S., Ron D., Barak S. (2014). Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol 48(3):243-52 . PDF

Neasta J., Barak S., Ben Hamida, S., Ron D. (2014) mTOR: A Key Player in Neuroadaptations Induced by Drugs of Abuse. Journal of Neurochemistry 130(2):172-84. PDF

Barak S., Liu F., Ben Hamida, S., Yowell V.Q, Neasta J., Kharazia V., Janak P.H., Ron D. (2013). Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse. Nature Neuroscience, 16, 1111-1117. PDF

Article highlighted in: Shen H. Blocking boozy memories reduces risk of relapse. Nature News.

Ahmadiantehrani S., Barak S., Ron, D (2014). GDNF is a novel alcohol-responsive gene in the VTA: Implications for the development and persistence of excessive drinking. Addiction Biology 19(4):623-33. PDF

Warnault V., Darque E., Levine A., Barak S., Ron D. (2013). Chromatin remodeling – a novel strategy to control excessive alcohol drinking. Translational Psychiatry 3, e231. PDF

Davies D.L., Finn D., Barak S., Ron D., Liang J., Olsen R.W. (2013). Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcoholism: Clinical and Experimental Research 37(1):8-15. PDF

 

Griebel G., Pichat Ph., ; Guillot E., Pruniaux M.P., Beeské S., Lopez-Grancha M., Genet E., Terranova J.P., Castro A., Sanchez J.A., Black M.D., Varty G., Weiner I., Arad M., Barak S., De Levie, A., Guillot E. (2012) SAR110894, a potent histamine H3-receptor antagonist, displays procognitive and awakening effects in rodents. Pharmacology, Biochemistry and Behavior, 102(2):203-214. PDF

Barak S., Ben Hamida S. (2012). Memory erasure, enhanced extinction and disrupted reconsolidation. Journal of Neuroscience 32(7):2250 –2251. PDF

Barak S., Ahmadiantehrani S., Kharazia V., Ron, D. (2011). Positive autoregulatory feedback loop of GDNF in the ventral tegmental area: implications for alcohol abuse disorders. Translational Psychiatry, 1 (e60): 1-9.  PDF

Barak S., Carnicella S., Yowell Q.V., Ron D. (2011). Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. Journal of Neuroscience, 31(27):9885-9894. PDF

Article highlighted in: Pickens C.L. and Calu D.J. (2011) AlcoholReward, Dopamine Depletion, and GDNF. Journal of Neuroscience. 31(42):14833-14834.

Gibb S.L., Jeanblanc J., Barak S., Yowell Q.V., Yaka R., Ron D. (2011). Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward. Journal of Neuroscience, 31(6):2180-2187. PDF

Barak S., Weiner I. (2011) Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacology, Biochemistry and Behavior, 99(2): 164-189. PDF

Dresner E., Barak S. (2011). Auditory and textual conversational multitasking. The Electronic Journal of Communication 21(3). PDF

Barak S., Weiner I (2011). The M1/M4 preferring antagonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: A selectively nonselective compound that can target multiple symptom domains of schizophrenia? International Journal of Neuropsychopharmacology 14(9): 1233-1246. PDF

Black M.D., Stevens R.J., Rogacki N., Featherstone R.E., Senyah Y., Giardino O., Borowsky B., Stemmelin J., Cohen C., Pichat Ph., Arad M., Barak S., De Levie A. Weiner I., Griebel G., Varty G.B. (2011). AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology, 215(1):149-63. PDF

Wang J., Carnicella S., Ahmadiantehrani S., He D-Y., Barak S., Kharazia V., Ben Hamida S., Zapata A., Shippenberg T.S., Ron, D. (2010). Nucleus accumbens-derived GDNF is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. Journal of Neuroscience, 30(43):14502-14512. PDF

Barak S., Weiner I. (2010) Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology, 35: 1073-1082. PDF

Barak S., Weiner I (2010). Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology 209(2): 175-184. PDF

Barak S. (2009). Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behavioural Brain Research, 204(2):335-51. PDF

 

Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. (2009). Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 34 (7): 1753-1763. PDF

Barak S., Weiner I. (2009). Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. International Journal of Neuropsychopharmacology, 12(2): 227-241. PDF

Black M., Varty GB., Arad M., Barak S., De Levie A., Boulay D., Pichat Ph., Griebel G., Weiner I. (2009). Procognitive and antipsychotic efficacy of Glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia. Latent inhibition studies in the rat. Psychopharmacology, 202(1-3): 385-396. PDF

Dresner E., Barak S. (2009). Effects of visual spatial structure on textual conversational multitasking. Communication Quarterly 57(1): 104-115. PDF

Barak S., Weiner I. (2007). Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 32(5): 989-999. PDF

​Dresner E., Barak S. (2006). Conversational multitasking in interactive written discourse as a communication competence. Communication Reports 19(1): 70-78. PDF

©2020 by Barel Weiner

barelkess.w@gmail.com